Investors & Media

Stock Info
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD).

BrainStorm Presentation on New Biomarker Data - NurOwn® at the 32nd International Symposium on ALS/MND

Brainstorm’s December 7, 2021 Presentation on new Biomarker data at the 32nd International Symposium on ALS/MND.

Corresponding Presentation

Recent News
May 19, 2023

- Presentation by Co-CEO Stacy Lindborg, Ph.D., held at 2023 ALS Drug Development Summit - Summit Focused On Transforming Translational Tools to Accelerate Future ALS Approvals NEW YORK, May 19,...

May 15, 2023

Biologics License Application for NurOwn® for the treatment of ALS to be subject of an upcoming FDA Advisory Committee Meeting Conference call and webcast at 8:00 a.m. Eastern Time today NEW...

May 9, 2023

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update...

View All

Monday, May 15, 2023
8:00am EDT

Participant Numbers:
Toll Free: 877 545 0523
International: 973 528 0016
Entry Code: 771387

Replay Numbers:
Toll Free: 877 481 4010
International: 919 882 2331
Replay Passcode: 48424

Press Release

View All

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds